Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis

References

• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642.
   Google Scholar
• Tyson N, Frank M. Childhood and adolescent obesity definitions as related to BMI, evaluation and management options. Best Pract Res Clin Obstet Gynaecol. 2018;48:158–164.
   Google Scholar
• Cardel MI, Jastreboff AM, Kelly AS. Treatment of adolescent obesity in 2020. JAMA. 2019;322:1707–1708.
   Google Scholar
• Nicolucci A, Maffeis C. The adolescent with obesity: what perspectives for treatment? Ital J Pediatr. 2022;48:9.
   Google Scholar
• Selvendran SS, Penney NC, Aggarwal N, et al. Treatment of obesity in young people—a systematic review and meta-analysis. Obes Surg. 2018;28:2537–2549.
   Google Scholar
• Cardel MI, Atkinson MA, Taveras EM, et al. Obesity treatment among adolescents: a review of current evidence and future directions. JAMA Pediatr. 2020;174:609–617.
   Google Scholar
• El-Kefraoui C, Olleik G, Chay MA, et al. Opioid versus opioid-free analgesia after surgical discharge: protocol for a systematic review and meta-analysis. BMJ Open. 2020;10:e035443.
   Google Scholar
• Shinohara K, Efthimiou O, Ostinelli EG, et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. BMJ Open. 2019;9:e027574.
   Google Scholar
• Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59:7–10.
   Google Scholar
• Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932–944.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–171.
   Google Scholar
• Wiegand S, l’Allemand D, Hübel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163:585–592.
   Google Scholar
• Garibay-Nieto N, Queipo-García G, Alvarez F, et al. Effects of conjugated linoleic acid and metformin on insulin sensitivity in obese children: randomized clinical trial. J Clin Endocrinol Metab. 2017;102:132–140.
   Google Scholar
• Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21:339–348.
   Google Scholar
• Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017;140:e20164285.
   Google Scholar
• Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab. 2012;25:41–49.
   Google Scholar
• Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013;98:322–329.
   Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–784.
   Google Scholar
• Rezvanian H, Hashemipour M, Kelishadi R, et al. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr. 2010;6:317–322.
   Google Scholar
• Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–576.
   Google Scholar
• Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152:817–822.
   Google Scholar
• Clarson CL, Brown HK, De Jesus S, et al. Effects of a comprehensive, intensive lifestyle intervention combined with metformin extended release in obese adolescents. Int Sch Res Notices. 2014;2014:659410.
   Google Scholar
• Wilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010;164:116–123.
   Google Scholar
• Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011;60:477–485.
   Google Scholar
• Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the management of childhood obesity: a randomized control trial. Child Obes. 2018;14:553–565.
   Google Scholar
• van der Aa MP, Elst MAJ, van de Garde EMW, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6:e228.
   Google Scholar
• Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12:18–28.
   Google Scholar
• Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873–2883.
   Google Scholar
• Weghuber D, Forslund A, Ahlström H, et al. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020;15:e12624.
   Google Scholar
• Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167:355–360.
   Google Scholar
• Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117–2128.
   Google Scholar
• Fox CK, Kaizer AM, Rudser KD, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity. 2016;24:2553–2561. Silver Spring
   Google Scholar
• Gadde KM, Atkins KD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother. 2020;21:1319–1328.
   Google Scholar
• Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. JAMA. 2021;326:129–130.
   Google Scholar
• Gudzune KA, Johnson VR, Bramante CT, et al. Geographic availability of physicians certified by the American board of obesity medicine relative to obesity prevalence. Obesity. 2019;27:1958–1966. (Silver Spring
   Google Scholar
• Czepiel KS, Perez NP, Campoverde Reyes KJ, et al. Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol (Lausanne). 2020;11:290.
   Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174.
   Google Scholar
• Correll CU, Sikich L, Reeves G, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19:69–80.
   Google Scholar
• Fox CK, Marlatt KL, Rudser KD, et al. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54:19–24.
   Google Scholar
• Camilleri M, Acosta A. Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointest Endosc. 2016;83:48–56.
   Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719–1730.
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
   Google Scholar
• Hatoum IJ, Stylopoulos N, Vanhoose AM, et al. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab. 2012;97:E1023–E1031.
   Google Scholar
• Iepsen EW, Zhang J, Thomsen HS, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 2018;28:23–32.e3.
   Google Scholar